Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Faculty of Medicine, University of Oslo, Oslo, Norway.
Diabetes Metab Res Rev. 2019 Mar;35(3):e3114. doi: 10.1002/dmrr.3114. Epub 2019 Jan 7.
The risk of gestational diabetes mellitus (GDM) is increased in overweight and obese women potentially involving secreted mediators from adipose tissue. Our main aim was to evaluate if circulating adipokines and monocyte/macrophage markers were dysregulated in GDM and the influence body mass and indices of glucose metabolism had on this association. We further explored if early detection of these markers improved prediction of GDM and if they remained modified during long-term follow-up.
Population-based prospective cohort study in 273 pregnant women with markers measured four times during pregnancy and at 5-year follow-up.
sCD163 was higher (25% at 14-16 weeks, P < 0.001) and adiponectin lower (-17% at 14-16 weeks, P < 0.01) early in pregnancy and at 5-year follow-up in GDM women, independent of BMI, and other GDM risk factors. Leptin, adiponectin, and chemerin were robustly associated with glucose metabolism throughout pregnancy while sCD163 was inversely associated with β-cell function early in pregnancy in women with increased BMI. Finally, the markers at 14 to 16 weeks displayed modest discriminatory properties with regard to prediction of GDM (AUC < 0.7). Using a combination of fasting glucose and sCD163, 53% of GDM could be identified when 25% of the population scored positive suggesting some merit in a multimarker approach.
sCD163 and adiponectin were dysregulated in GDM, independent of body mass. None of the adipokines or monocyte/macrophage activation markers displayed clinically useful properties alone for early detection of GDM. Activation of monocytes/macrophages may be an important event in the early development of GDM.
超重和肥胖的女性发生妊娠期糖尿病(GDM)的风险增加,这可能涉及脂肪组织分泌的介质。我们的主要目的是评估循环脂肪因子和单核细胞/巨噬细胞标志物在 GDM 中是否失调,以及体重和葡萄糖代谢指标对这种关联的影响。我们进一步探讨了这些标志物的早期检测是否能改善 GDM 的预测,以及它们是否在长期随访中仍然发生改变。
这是一项基于人群的前瞻性队列研究,共纳入 273 名孕妇,在怀孕期间和 5 年随访时进行了 4 次标志物检测。
GDM 女性在妊娠早期和 5 年随访时 sCD163 更高(14-16 周时增加 25%,P<0.001),脂联素更低(14-16 周时减少 17%,P<0.01),与 BMI 和其他 GDM 危险因素无关。瘦素、脂联素和 chemerin 在整个孕期与葡萄糖代谢密切相关,而 sCD163 在 BMI 增加的孕妇妊娠早期与β细胞功能呈负相关。最后,14 至 16 周时的标志物在预测 GDM 方面具有适度的区分能力(AUC<0.7)。使用空腹血糖和 sCD163 的组合,当 25%的人群呈阳性时,可以识别出 53%的 GDM,表明多标志物方法有一定的价值。
sCD163 和脂联素在 GDM 中失调,与体重无关。在单独用于早期检测 GDM 时,没有一种脂肪因子或单核细胞/巨噬细胞激活标志物具有临床有用的特性。单核细胞/巨噬细胞的激活可能是 GDM 早期发展的一个重要事件。